** Shares of EyePoint Pharmaceuticals rise 36.5% to five-month high of $12.96
** Co says its drug, Duravyu, showed an improvement in how well patients can see objects at a distance in a mid-stage trial testing it in diabetic macular edema $(DME.AU)$
** DME is an eye condition that causes blurry vision in people with diabetes
** Co expects to report the full topline results in Q1 2025
** Including session's move, EYPT stock down 50.8% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。